Eli Lilly and Company (LLY)vsZhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
ZYBT
Zhengye Biotechnology Holding Limited Ordinary Shares
$1.55
-2.52%
HEALTHCARE · Cap: $76.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 68364% more annual revenue ($79.67B vs $116.36M). LLY leads profitability with a 33.5% profit margin vs -60.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
ZYBT
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -25.2% — below average capital efficiency
Revenue declined 40.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : ZYBT
The strongest argument for ZYBT centers on Price/Book.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : ZYBT
The primary concerns for ZYBT are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while ZYBT is a turnaround play — different risk/reward profiles.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 24/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Zhengye Biotechnology Holding Limited Ordinary Shares
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm specializing in the development and commercialization of advanced biopharmaceutical products aimed at addressing critical medical needs. With a robust pipeline and proprietary technologies, ZYBT is well-positioned to enhance treatment outcomes across multiple therapeutic areas. The company's commitment to rigorous research and development, coupled with a focus on quality and innovation, underscores its potential for sustainable growth and value creation for investors in the competitive biotechnology landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?